SCHEMBL1591088

SCHEMBL1591088

Cc1cc(Oc2ccc(NS(=O)(=O)c3cccc4ccccc34)cc2)c2cc(F)ccc2n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 2/20 0.60
▸ BCL2L1 Q07817 1/20 0.50
▸ MCL1 Q07820 1/20 0.50
▸ TSHR P16473 1/20 0.47
▸ BRAF P15056 2/20 0.46
▸ MAPK14 Q16539 1/20 0.46
▸ CYP17A1 P05093 1/20 0.45
▸ AXL P30530 1/20 0.44
▸ PTPN2 P17706 1/20 0.44
▸ PTPN1 P18031 1/20 0.44
▸ PTPN5 P54829 1/20 0.44
▸ RORA P35398 1/20 0.43
▸ RORC P51449 1/20 0.43
▸ NR1H2 P55055 1/20 0.43
▸ NR1H4 Q96RI1 1/20 0.43
▸ FFAR1 O14842 1/20 0.43
▸ FFAR4 Q5NUL3 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ PFKFB3 Q16875 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1591224 0.87 FFAR1 (0.56) PGRTSHRBRAFFFAR1FFAR4
SCHEMBL1592197 0.86 RORC (0.51) PGRBRAFAXLRORCFFAR1
SCHEMBL1591137 0.83 PGR (0.50) PGRTSHRBRAFMAPK14RORC
SCHEMBL1590907 0.82 PGR (0.58) PGRBRAFMAPK14AXLPTPN2
SCHEMBL10328504 0.82 PGR (0.48) PGRTSHRCYP17A1PTPN2PTPN1
SCHEMBL1592072 0.80 PGR (0.55) PGRFFAR1FFAR4
SCHEMBL1591817 0.79 ACLY (0.52) BCL2L1MCL1
SCHEMBL1591259 0.79 ATM (0.55) BCL2L1MCL1TSHRBRAFMAPK14
SCHEMBL1591770 0.79 ACLY (0.45) BCL2L1MCL1AXLALDH1A1HTT
SCHEMBL1591551 0.79 AXL (0.47) BRAFMAPK14AXLRORCHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 — — US claimed
US-9206130-B2 Quinoline derivatives as AXL kinase inhibitors MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-12-08 — — US disclosed
US-9206130-B2 Quinoline derivatives as AXL kinase inhibitors MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-12-08 — — US disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 — — US disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 — — US disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS AXL, FLT3, TYRO3 PGR 2847/4885BCL2L1 1431/4885MCL1 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback